MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
Kovacs
Kalman
K
Scheithauer
Bernd W
BW
Lombardero
Matilde
M
McLendon
Roger E
RE
Syro
Luis V
LV
Uribe
Humberto
H
Ortiz
Leon D
LD
Penagos
Luis C
LC
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D015254:DNA Modification Methylases / Q000096:biosynthesis*; D045643:DNA Repair Enzymes / Q000096:biosynthesis*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis*
D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide